CELLVAX THERAPEUTICS

CellVax Therapeutics is a privately-held clinical-stage company active in research, development, and innovation on human immunodiagnostic and autologous anticancer vaccines. CellVax Therapeutics has developed a proprietary autologous tumor cell-based cancer immuno-therapy platform... CellVax Therapeutics plays a unique role in cancer immunotherapy by developing a platform that converts the patient's own cancer cells into an antigen-presenting state ("Tumor Presenting Cells"). The process involves cultivating tumor cells with a combination of cytokines in a specific media, which stimulates the de novo expression of MHC class II molecules on the surface of tumor cells. Solid tumor cells, like other non-immunological cells, do not naturally present MHC class II, a molecule critically responsible for peptide presentation to T helper cells to trigger an immune response. These modified tumor cells ("Tumor-Presenting Cells") are then incubated with a foreign antigen, which is then..